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ABSTRACT 
Hydro-alcoholic fruit extract of Cordia myxa was considerably effective on curing acute inflammation in mouse 
model. Previous studies suggested significant anti-inflammatory activities as well as potential anticancer agent of 
α-amyrins in seeds. Inhibition of Cyclooxygenase-2 (COX-2) and 5-Lipooxygenase (5-LOX) is significant in 
cancer prevention and therapeutics although this inhibition with chemo-drugs has its own side-effects. It is 
shown that these enzymes pathways are related to several cancers including colon, breast and lung cancer. This 
study was conducted based on Cordia species’ α-amyrins as a safer natural anti-cancer compound for inhibition 
of COX-2 and 5-LOX enzymes by molecular docking. The X-ray crystal structure of COX2 / 5-LOX enzymes 
and α-amyrins was retrieved and energetically minimized respectively. The binding site and surface of enzymes 
were detected. Docking studies were performed by AutoDock 4.2 using Lamarckian genetic algorithm (LGA). 
Finally drug likeness, molecular pharmacokinetic properties and toxicity of α-amyrins was calculated. Molecular 
Docking revealed hydrogen and hydrophobic interactions between α-amyrins with both active sites of COX-2 
and 5-LOX enzymes. Interestingly, it covalently bonded to Fe cofactor of 5-LOX enzyme and chelated this mol-
ecule. Base on binding energies (∆G) α-amyrin has more inhibitory effects on 5-LOX (-10.45 Kcal/mol) than 
COX-2 (-8.02 Kcal/mol). Analysis of molecular pharmacokinetic parameters suggested that α-amyrins complied 
with most sets of Lipinski's rules, and so it could be a suitable ligand for docking studies. Eventually, bioactivity 
score showed α-amyrins possess considerable biological activities as nuclear receptor, enzyme inhibitor, GPCR 
and protease inhibitor ligand. These results clearly demonstrate that α-amyrins could act as potential highly se-
lective COX-/5-LOX inhibitor. Also, it is a safe compound in comparison with classical non-steroidal anti-
inflammatory drugs (NSAIDs) that are known as cancer preventive agents, since it is free of side effects on hu-
man body and it can be a promising drug for cancer therapeutics. 
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INTRODUCTION 
Now it is widely accepted that COX-2 
plays a pivotal role not only in inflammation 
but also in tumor-genesis. It is indicated that 
COX-2-selective inhibitors can be a novel 
class of therapeutic agents for colorectal pol-
yposis and cancer (Sano et al., 1995; Oshima 
et al., 1996). COX-2 contributes to tumor 
formation and its growth. Both tumor and 
stromally derived COX-2 could influence 
tumor angiogenesis and immune function. 
Furthermore, COX-2 over-expressed in half 
of benign polyps and 80 - 85 % of adenocar-
cinomas and inhibitors of cyclooxygenase 
are preventive for colon cancer (Williams et 
al., 1999). Thus, several studies indicate that 
nonsteroidal anti-inflammatory drugs reduce 
the risk of colon cancer.  
Moreover, the findings suggest that an 
increase in COX-2 expression associated 
with the development of breast cancer (Har-
ris et al., 2000) as well as lung cancer and 
possibly with acquisition of an invasive and 
metastatic phenotype (Hida et al., 1998). The 
chemo preventive activity of NSAIDs 
against breast cancer provides the first evi-
dence that cyclooxygenase-2 blocking agent, 
celecoxib-α specific COX-2 inhibitor sup-
pressed the incidence, multiplicity, and size 
of malignant breast tumors, possesses strong 
chemopreventive activity against mammary 
carcinogenesis (Harris et al., 2000). 
On other hand, it is confirmed that LOX 
pathway receptor expression was found in 
the majority of cancers evaluated specifically 
in ovarian cancer. Dual 5-LOX/COX inhibi-
tors are potential new drugs since they act by 
blocking the formation of both prostaglan-
dins and leucotrienes but do not affect lipox-
in formation. Such combined inhibition 
avoids some of the disadvantages of selec-
tive COX-2 inhibitors and spares the gatroin-
testinal mucosa (Martel-Pelletier et al., 
2003). Recently, it was indicated that dual 
inhibition of 5-LOX and COX-2 suppresses 
colon cancer effectively (Ye et al., 2005). 
The most of chemical inhibitors which inhib-
it COX-2/5-LOX have various side effects 
including gastrointestinal ulcerogenic activi-
ty and bronchospasm.  
Inflammation, however, linked to cancer 
as tumors often arose at sites of chronic in-
flammation and that inflammatory cells were 
present in biopsied samples from tumors. In-
flammatory diseases increase the risk of de-
veloping many types of cancer and non-
steroidal anti-inflammatory drugs reduce the 
risk of developing certain cancers (such as 
colon and breast cancer) and reduce the mor-
tality caused by these cancers (Mantovani et 
al., 2008). In the light of these facts inhibi-
tion of an inflammation as a cancer inducer 
might have a role as important as cancer 
treatment. 
Arachidonic acid (AA) pathway plays 
key roles in inflammatory response in which 
AA is oxygenated by the enzymes cyclooxy-
genase (COX) and lipooxygenase (LOX) and 
is then transformed into a variety of products 
which mediate or modulate inflammatory re-
actions (Martel-Pelletier et al., 2003). There 
are two distinct established isozymes (COX-
1 and COX-2) for COX. COX-2 is primarily 
responsible for inflammation (Julémont et 
al., 2004; FitzGerald and Patrono, 2001). Ac-
tivity of 5-LOX enzyme in body produces 
Leucotriene compounds that contribute in in-
flammatory process as well (Julémont et al., 
2004; Pelletier et al., 2001; Martel-Pelletier 
et al., 2003). Inhibition of COX-2 and 5-
LOX has been considered an effective mech-
anism for inflammatory preventions (Martel-
Pelletier et al., 2003). Inhibitors of both 
COX-2/5-LOX enzyme are known as effec-
tive promising regimes in controlling molec-
ular processes of inflammation and showed 
minimal adverse effects compared to non-
steroidal anti-inflammatory drugs (NSAIDs) 
(Julémont et al., 2004). 
In comparison to new drugs, herbal med-
icines and their relative compounds are fre-
quently used to treat different inflammatory 
conditions, such as lung and skin inflamma-
tions as well as chronic diseases (Dixit and 
Mittal, 2013; Garg et al., 2012). Recently, 
we done an in-vitro study on anti-inflam-
matory properties of Cordia myxa fruit and 
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results showed that the hydro-alcoholic ex-
tract was considerably effective in treatment 
of acute inflammation in rat (Ranjbar et al., 
2013). Cordia species plants are increasingly 
being referred to as a rich source of anti-
inflamatory compounds (Ficarra et al., 1995; 
Dixit and Mittal, 2013). Moreover, several 
studies on Cordia species revealed analgesic, 
anti-inflammatory and other properties of 
different part of this plant (Ficarra et al., 
1995; Al-Awadi et al., 2001; Shahapurkar 
and Jayanthi, 2011). It contains phytochemi-
cals which have immunomodulatory activity. 
Previous in vitro studies suggested that sig-
nificant anti-inflammatory activity of seed is 
due to its active ingredients such as α-
amyrins and taxifolin-3,5-dirhamnoside 
(71.4 %, 67.8 % respectively) (Nariya et al., 
2011).  
Isolation, characterization and screening 
of in silico/in vitro pharmacokinetics of ac-
tive compounds from medicinal plants is 
common today and drug discovery tech-
niques such as molecular modeling and 
docking are widely used to elucidate their ef-
fects on body (Geysen et al., 2003). Ligand 
binding interactions with the receptor (espe-
cially protein targets) are central pathway to 
numerous biological process and designing 
therapeutic agents (Morris et al., 2009). In 
this paper, we report the screening of α-
amyrins as natural potent anti-cancer as well 
as anti-inflammatory compounds derived 
from Cordia species seed for dual inhibition 
of COX2 and 5-LOX enzymes by molecular 
docking and evaluate its drug likeness and 
toxicity, to study the binding pattern and 
characteristics of the molecule for applica-
tion as a novel drug in treatment of inflam-
matory diseases. 
 
METHODS 
Molecular structures and energy  
minimization  
The X-ray crystal structure of Cyclooxy-
genase-2 (COX2) (PDB ID 4PH9) and 5-
lipoxygenase enzyme (PDB ID 3vv9) were 
retrieved from protein data bank 
(www.pdb.org). Then, water molecules were 
removed and the enzymes cleaned from any 
unwanted interactions. Two selected struc-
ture were energetically minimized by SPDV 
viewer software tool with GROMOS96 im-
plementation. The 3D chemical structure of 
α-amyrins (CID: 73170) was retrieved 
through the PubChem-compound database at 
NCBI webserver, USA 
(www.pubchem.ncbi.nlm.nih.gov). Also, 
Ligand (α-amyrins) was minimized by Che-
mAxon software. 
 
Preparation of receptors for docking 
First, for correct ionization and tautomer-
ic states of amino acid residues, all nonpolar 
hydrogens were merged (removed) and par-
tial atomic charges were assigned using the 
Gasteiger-Marsili method. Then charges 
were added to enzyme structures and Koll-
man United Atom charges and atomic salva-
tion parameters were assigned. In continue 
incomplete side chains replaced using Dun-
brack rotamer library by Chimera 1.8 soft-
ware. The binding site and surface of en-
zymes were detected based on the previous 
reported data beside the catalytic domain of 
the enzyme just near the metal ion Fe in both 
structures (Gilbert et al., 2011; Wang et al., 
2010). 
 
Molecular docking 
Molecular docking was carried out in or-
der to evaluate a possible binding mode be-
tween alpha-amyrin and COX2 and 5-LOX 
active sites. Docking in virtual-screening 
gives suitable indication of the possible bio-
logical activities of compounds and reduces 
cost and time of drug discovery. It also esti-
mates the strength of the binding, the energy 
of the complex and calculates the binding af-
finity using scoring functions.  
The docking studies were performed us-
ing AutoDock 4.2. The Lamarckian genetic 
algorithm (LGA), considered one of the best 
docking methods available in AutoDock, 
was selected to perform the molecular dock-
ing studies (Morris et al., 2009). AutoDock 
has reported to have high accuracy in pre-
dicting binding free energies between ligand 
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and receptor by considering that the receptor 
is rigid while ligand is free to move, with a 
comparatively low standard error. Therefore, 
COX2 and 5-LOX conformational flexibility 
was neglected by rigid receptor docking. All 
rotatable bonds were assigned for the ligands 
(Morris et al., 2009, Cosconati et al., 2010). 
To assign the perfect grid of each ligand, 
grid box values were obtained by trial and 
error and from previous research using Au-
toGrid. Grid maps with 126 -126- 126 points 
(the x, y and z directions) were made and the 
grid-point spacing was considered 0.375 Å. 
Each map was centered such that it covered 
the entire protein especially all possible 
binding sites. The number of docking inde-
pendent runs was set to 50 with the step sizes 
of 0.2 Å and 5°. 
Final docked conformations (20 con-
formers for each docking) were clustered 
based on a tolerance of 1 Å all-atom RMSD 
from the lowest-energy structure. The 
docked conformations of α-amyrins were 
ranked into clusters based on the binding en-
ergy and the most favorable binding confor-
mation with the lowest free energies was se-
lected as the binding pose and visually ana-
lyzed. Hydrogen bonding and hydrophobic 
interactions between α-amyrins and COX2 
and 5-LOX were analyzed using Auto Dock 
Tools and Chimera 1.8 software. 
 
Drug likeness and toxicity evaluation of the 
Ligand 
Molinspiration server 
(www.molinspiration.com) was used to cal-
culate the α-amyrins drug likeness and mo-
lecular pharmacokinetic properties. Drug 
likeliness indexes assist to the ideal proce-
dure of rejection nonviable ligand com-
pounds before they are even synthesized. 
Synthetic and natural compounds using as 
drug against diseases need to under the rules 
and conditions. Drug likeness may be de-
fined as a complex balance of various mo-
lecular properties and structure features 
which determine whether particular molecule 
is similar to the known drugs. 
This tool was used to perform prediction 
of bioactivity score for the most important 
drug targets as well as QSAR (Structure-
activity relationship) studies in order to iden-
tify potential activators of biological targets. 
It offers free online services for calculation 
of important molecular properties (logP, po-
lar surface area, number of hydrogen bond 
donors and acceptors). 
Lipinski's Rule of Five was used to eval-
uate drug likeness, or determine if a chemi-
cal compound with a certain pharmacologi-
cal or biological activity has properties that 
would make it potentially applicable as an 
oral drug. The rule describes molecular 
properties important for a drug's pharmaco-
kinetics in the human body, including their 
absorption, distribution, metabolism, and ex-
cretion ("ADME”). Lipinski's rule considers 
a compound as a drug if it satisfies the fol-
lowing criteria: not more than 5 hydrogen 
bond donors (number of hydrogen bond do-
nors ≤ 5), not more than 10 hydrogen bond 
acceptors (number of hydrogen bond accep-
tors ≤ 10), A molecular mass not greater than 
500 Daltons (molecular weight ≤ 500), An 
octanol-water partition coefficient log P not 
greater than 5 (logP ≤ 5), Molecules violat-
ing more than one of these rules may have 
problems with bioavailability (Lipinski et al., 
2001). The compound that had more than 
one violation from these rules should be 
eliminated from the study (docking) because 
of bioavability problems. 
The Lipinski’s rule of five parameters 
and total polar surface area (TPSA) have 
shown to correlate with drug absorption. 
Molinspiration tools analysis Lipinski’s 
rule of five, these molecular properties are 
logP, polar surface area (TPSA), molecular 
weight, number of atoms, number of O or N, 
number of OH or NH, number of rotatable 
bonds, volume, drug likeness includes G pro-
tein coupled receptors (GPCR) ligand, ion 
channel modulator, kinase inhibitor, nuclear 
receptor and enzyme inhibitor ligand, and 
eventually number of violations to Lipinski’s 
rule for ligand.  
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Furthermore, bio-safety of the α-amyrins 
molecule inside the human body was also 
explored. Toxicity analysis was done by tak-
ing advantages of Toxtree v.2.6.0 software. 
 
RESULTS 
Molecular Docking revealed interaction 
between α-amyrins with both active site of 
COX-2 and 5-LOX enzyme. α-amyrins in-
teractions was stabilized by single hydrogen 
bond within the active site of amino acid 
GLN290 of COX-2 (Figure 1: A1 and A2) 
and ASN554 of LOX-5 (Figure 1: B1 and 
B2), and besides hydrophobic interactions. 
Inspections of the active site pockets in 
both enzymes revealed it is located near Fe. 
Interestingly, α-amyrins directly bind to Fe 
cofactor of 5-LOX enzyme (by covalent 
bond) and it may chelate this molecule. In 
case of COX-2, α-amyrins is closely located 
near Hem. 
Docking study of α-amyrins on binding 
sites of 5-LOX and COX-2 shows that lig-
ands are good 5-LOX/COX-2 inhibitor and 
α-amyrins could be considered as promising 
inflammatory inhibitors of natural origin. Al-
so, inspection of binding energies and inter-
action between cofactors (Fe or Hem) re-
vealed α-amyrins has more inhibitory effects 
(binding affinity) on 5-LOX enzyme than 
COX-2 (Table 1). 
 
Results of drug likeness and toxicity  
estimations 
Molecular physicochemical and the drug 
likeness are the two most significant proper-
ties to be considered for a compound to be-
come a successful drug candidate. 
Analysis molecular pharmacokinetic pa-
rameters are arranged in Table 2. These re-
sults suggested that α-amyrins complied with 
the most of the Lipinski's rules (as it de-
scribed in method) and has low polar surface 
area (PSA). However, LogP parameter is 
greater than 5 and violate from the rules. 
Term of LogP value shows the hydrophilici-
ty character (lipophilicity) of compound and 
greatly affects absorption or permeation. 
 
 
Figure 1: The binding modes of α-amyrins in the 
allosteric binding site pocket of COX-2 (A1 and 
A2) and 5-LOX (B1 and B2) enzymes. Arrows in 
A1 and B1 figures show hydrogen bonds be-
tween ligand and active sites. 
 
 
So, α-amyrins might desirably have 
passed through the Lipinski’s rule of five cri-
teria if some structural modifications occur 
to improve its membrane penetrability, alt-
hough some successful commercial drugs do 
not follow some Lipinski's rules. Since α-
amyrins rule number 5 violations was only 
seen in one parameter, thus this ligand could 
be checked for Docking Studies. 
Bioactivity score of α-amyrins against 
GPCR ligand, ion channel modulator, kinase 
inhibitor, nuclear receptor ligand, protease 
inhibitor and enzyme inhibitory activity were 
evaluated and summarized in Table 3. The 
molecule having bioactivity score more than 
0.00 is likely to possess considerable biolog-
ical activities, values -0.50 to 0.00 are ex-
pected to be moderately active and if score is 
less than -0.50, it is presumed to be inactive . 
With regard to bioactivity score, α-amyrins 
possess considerable biological activities as 
nuclear receptor, Enzyme inhibitor, GPCR 
and protease inhibitor ligand, respectively. 
Toxicity of novel drug candidate is one 
of the major reasons for failure of drug dis-
covery and screening efforts. Finally, toxici-
ty analysis α-amyrins were subjected to tox-
icity assessment study by using Toxtree 
v.2.6.0. α-amyrins found to be free from 
high risks of undesired effects. 
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Table 1: ∆G (binding energy), hydrogen bonds along with their distances between the α-amyrins and 
active sites of COX2 and 5-LOX 
Ligand Structure and Molecular Formula 
Receptors 
COX2 5-LOX 
∆G
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α-
amyrins 
C30H50O 
 
 
 
- 8.02 1 GLN290 2.09 -10.45 1 ASN554 2. 
 
Table 2: Molecular pharmacokinetic properties 
Ligand miLogPa TPSAb MWc natomsd nONe nOHNHf nviola-tionsg nrotb
h volumei
α-
amyrins 8.08 20.23 426.73 31 1 1 1 0 461.05 
a the logarithm of octanol/water partition coefficient, b Polar surface area, c molecular weight d number of non hydrogen atoms,  
e number of hydrogen bond acceptors ( O and N atoms), f number of hydrogen bond donors ( OH and NHgroups), g number of 
rule of 5 violations, h number of rotatable bonds, i molecular volume.  
 
Table 3: Bioactivity score (drug-likeness property) analysis of α-amyrins  using Mol inspiration online 
software tool 
Ligand GPCR  ligand 
Ion channel 
modulator 
Kinase  
inhibitor 
Nuclear  
receptor  
ligand 
Protease 
inhibitor 
enzyme  
inhibitory 
α-amyrins 0.22 -0.02 -0.41 0.79 0.19 0.60 
 
 
DISCUSSION AND CONCLUSION 
Although NSAIDs (such as aspirin, ibu-
profen, naproxen) showed significant effica-
cy as anti-inflammatory and analgesic agents 
for treatment of inflammatory diseases and 
have profound effects on cancer as a preven-
tive agent, long-term administration of 
NSAIDs lead to side-effects including renal 
failure and gastrointestinal (GI) symptoms 
including: mucosal lesions, bleeding, peptic 
ulcer, and intestinal inflammation which 
causes perforation and strictures in small and 
large intestines. In contrast, the 5-LOX/ 
COX-2 inhibitors profile showed they are 
free of gastrointestinal toxicity (Martel-
Pelletier et al., 2013). Cordia spp. and sever-
al plant extracts and their isolated com-
pounds showed successful anti-inflammatory 
activity (Dixit and Mittal, 2013; Ranjbar et 
al., 2013) and they can be useful as cancer 
prevention or drug either (Parisotto et al., 
2012).  
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In the present study, α-amyrins assessed 
for its anti cancer and anti-inflammatory ac-
tivities using molecular docking with COX-
2/5-LOX enzymes and also drug likeness 
and toxicity analysis. This compound exhib-
ited significant anti cancer and anti-
inflammatory activity, by inhibition of both 
COX-2 and 5-LOX enzyme. Its binding af-
finity with 5-LOX (∆G=-10.45 Kcal/mol) 
was more than COX-2 (∆G=-8.02 Kcal/mol), 
and it also covalently bonded to Fe. Also, 
hydrophobic interactions and hydrogen 
bonds between GLN290 and ASN554 with 
ligand were found in COX-2 and LOX-5, re-
spectively. 
The results of docking investigation sug-
gest a good binding interaction which ex-
plains the significant biological activity of α-
amyrins. Cordia extract by its active com-
pounds could be a safe herbal alternative to 
COX-2/5-LOX inhibitor drugs for both can-
cer and inflammation, and offers a number of 
advantages such as lower side effects on 
human body and lower cost.  
Moreover, blocking the COX-2 enzyme 
completely is harmful for cardiovascular 
health and blocking a part of COX-2 activity 
is favorable. By respect to binding energy, 
hydrogen bonds and drug likeness of α-
amyrins, it may partially block this enzymes 
and relief the pain. 
Furthermore, high bioactivity score for 
nuclear receptor, GPCR and protease inhibi-
tor is reflection of probable potential of this 
compound on these proteins and interesting-
ly it needs further investigations. 
Our computational results clearly 
demonstrate that the α-amyrins from Cordia 
spp. seed possess dual inhibitory effect on 
COX-2/5-LOX enzyme activity and would 
be effective as a complementary drug for 
human anti-inflammatory regime consump-
tion. The identification and development of 
novel natural compounds with safe inhibito-
ry activity is an urgent need of pharmaceuti-
cal industry for achieving more effective 
drugs especially for such incurable diseases 
like cancer. 
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